KHK-IN-1 is primarily utilized in research settings to study metabolic pathways, particularly those involving ketohexokinase (KHK). It acts as an inhibitor of KHK, an enzyme that plays a critical role in fructose metabolism. By blocking KHK activity, this compound helps researchers investigate the effects of reduced fructose metabolism in various metabolic disorders, such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). Its application extends to exploring potential therapeutic strategies for these conditions by targeting fructose metabolism pathways. Additionally, KHK-IN-1 is used in preclinical studies to understand the role of KHK in cancer progression, as fructose metabolism has been linked to tumor growth and survival in certain cancers.